<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03881163</url>
  </required_header>
  <id_info>
    <org_study_id>Z7244J01</org_study_id>
    <nct_id>NCT03881163</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Pharmacokinetics, Safety and Tolerability of Single and Multiple Intravenous Doses of N-acetylcysteine (NAC) in Chinese Healthy Volunteers</brief_title>
  <official_title>Phase I Study to Evaluate Pharmacokinetics, Safety and Tolerability of Single and Multiple i.v. Doses of N-acetylcysteine (NAC) in Chinese Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zambon SpA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zambon SpA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single and multiple dose, single centre, open-label, one-way, pharmacokinetics,&#xD;
      safety and tolerability clinical trial of Phase I to be performed in Chinese healthy male and&#xD;
      female volunteers. Twenty-four (24) healthy male and female Chinese volunteers will be&#xD;
      included in the study. Drop-out subjects will not be replaced. The study has been designed in&#xD;
      agreement with the Chinese Technical Guideline on Clinical Pharmacokinetic Research of&#xD;
      Chemical Drugs, 18 March 2005 and the European Guideline on the Investigation of&#xD;
      Bioequivalence. No randomisation will take place in this study. All the participant will&#xD;
      receive the same treatment with the investigational medicinal product (IMP), i.e. NAC, 300&#xD;
      mg/ 3 mL solution for injection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 11, 2019</start_date>
  <completion_date type="Actual">January 18, 2020</completion_date>
  <primary_completion_date type="Actual">January 18, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>All the subjects enrolled in the study will receive the same treatment with the investigational medicinal product (IMP), i.e. NAC, 300 mg/ 3 mL solution injection as single dose and multiple dose regime. Single dose of IMP will be administered under fasting conditions on day 1 at 08:00 ±1 h. Multiple doses (5) of IMP will be administered twice a day (b.i.d.) on days 4 and 5 at 08:00 ±1 h and 20:00 ±1 h and one dose will be administered on day 6 at 08:00 ±1.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Drug Concentration (Cmax) After Single Dose of NAC</measure>
    <time_frame>On Day 1 and Day 2-At pre-dose (0) and 5 (at the end of the infusion), 8, 12, 15, 20, 25, 30, 60 minutes and 2, 4, 6, 8, 10, 12, 24 and 32 hours post-dose</time_frame>
    <description>To evaluate pharmacokinetic parameters of NAC in plasma after single administration of the investigational product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Achieve Cmax (Tmax) After Single Dose of NAC</measure>
    <time_frame>On Day 1 and Day 2-At pre-dose (0) and 5 (at the end of the infusion), 8, 12, 15, 20, 25, 30, 60 minutes and 2, 4, 6, 8, 10, 12, 24 and 32 hours post-dose.</time_frame>
    <description>To evaluate pharmacokinetic parameters of NAC in plasma after single dose administration of the investigational product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Elimination Rate Constant (Kel) After Single Dose of NAC</measure>
    <time_frame>On Day 1 and Day 2-At pre-dose (0) and 5 (at the end of the infusion), 8, 12, 15, 20, 25, 30, 60 minutes and 2, 4, 6, 8, 10, 12, 24 and 32 hours post-dose.</time_frame>
    <description>To evaluate pharmacokinetic parameters of NAC in plasma after single dose administration of the investigational product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-life (t1/2) After Single Dose of NAC</measure>
    <time_frame>On Day 1 and Day 2-At pre-dose (0) and 5 (at the end of the infusion), 8, 12, 15, 20, 25, 30, 60 minutes and 2, 4, 6, 8, 10, 12, 24 and 32 hours post-dose.</time_frame>
    <description>To evaluate pharmacokinetic parameters of NAC in plasma after single dose administration of the investigational product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve (AUC) After Single Dose of NAC</measure>
    <time_frame>On Day 1 and Day 2-At pre-dose (0) and 5 (at the end of the infusion), 8, 12, 15, 20, 25, 30, 60 minutes and 2, 4, 6, 8, 10, 12, 24 and 32 hours post-dose.</time_frame>
    <description>To evaluate pharmacokinetic parameters of NAC in plasma after single dose administration of the investigational product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of Distribution (Vd) After Single Dose of NAC</measure>
    <time_frame>On Day 1 and Day 2-At pre-dose (0) and 5 (at the end of the infusion), 8, 12, 15, 20, 25, 30, 60 minutes and 2, 4, 6, 8, 10, 12, 24 and 32 hours post-dose.</time_frame>
    <description>To evaluate pharmacokinetic parameters of NAC in plasma after single dose administration of the investigational product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Body Clearance (CLt) After Single Dose of NAC</measure>
    <time_frame>On Day 1 and Day 2-At pre-dose (0) and 5 (at the end of the infusion), 8, 12, 15, 20, 25, 30, 60 minutes and 2, 4, 6, 8, 10, 12, 24 and 32 hours post-dose.</time_frame>
    <description>To evaluate pharmacokinetic parameters of NAC in plasma after single dose administration of the investigational product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Amount of NAC Excreted in Urine [Ae(0-t)] After Single Dose of NAC</measure>
    <time_frame>On Day 1 and Day 2-At pre-dose (0) and 5 (at the end of the infusion), 8, 12, 15, 20, 25, 30, 60 minutes and 2, 4, 6, 8, 10, 12, 24 and 32 hours post-dose.</time_frame>
    <description>To evaluate pharmacokinetic parameters of NAC in plasma after single dose administration of the investigational product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Fraction of NAC Dose Excreted in Urine [Fe(0-t)] After Single Dose of NAC</measure>
    <time_frame>On Day 1 and Day 2-At pre-dose (0) and 5 (at the end of the infusion), 8, 12, 15, 20, 25, 30, 60 minutes and 2, 4, 6, 8, 10, 12, 24 and 32 hours post-dose.</time_frame>
    <description>To evaluate pharmacokinetic parameters of NAC in plasma after single dose administration of the investigational product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal Clearance (CLr) After Single Dose of NAC</measure>
    <time_frame>On Day 1 and Day 2-At pre-dose (0) and 5 (at the end of the infusion), 8, 12, 15, 20, 25, 30, 60 minutes and 2, 4, 6, 8, 10, 12, 24 and 32 hours post-dose.</time_frame>
    <description>To evaluate pharmacokinetic parameters of NAC in plasma after single dose administration of the investigational product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of the AUC(0-inf) Obtained by Extrapolation (%AUCextra)</measure>
    <time_frame>On Day 1 and Day 2-At pre-dose (0) and 5 (at the end of the infusion), 8, 12, 15, 20, 25, 30, 60 minutes and 2, 4, 6, 8, 10, 12, 24 and 32 hours post-dose.</time_frame>
    <description>To evaluate pharmacokinetic parameters of NAC in plasma after single dose administration of the investigational product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Concentration at Steady-state After Multiple Doses of NAC</measure>
    <time_frame>On Day 4 and Day 5 -At pre-dose. On Day 6 and Day 7-At pre-dose (0) and 5 (at the end of the infusion), 8, 12, 15, 20, 25, 30, 60 minutes and 2, 4, 6, 8, 10, 12, 24 and 32 hours post-dose.</time_frame>
    <description>To evaluate pharmacokinetic parameters of NAC in plasma after multiple dose administration of the investigational product.&#xD;
Css_max = maximum NAC plasma concentration at steady-state, Css_min=minimum plasma concentration at steady-state, Css_avg=average NAC plasma concentration at steady-state.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Achieve Css_max (tss_max) After Multiple Doses of NAC</measure>
    <time_frame>On Day 4 and Day 5 -At pre-dose. On Day 6 and Day 7-At pre-dose (0) and 5 (at the end of the infusion), 8, 12, 15, 20, 25, 30, 60 minutes and 2, 4, 6, 8, 10, 12, 24 and 32 hours post-dose.</time_frame>
    <description>To evaluate pharmacokinetic parameters of NAC in plasma after multiple dose administration of the investigational product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve at Steady State After Multiple Doses of NAC</measure>
    <time_frame>On Day 4 and Day 5 -At pre-dose. On Day 6 and Day 7-At pre-dose (0) and 5 (at the end of the infusion), 8, 12, 15, 20, 25, 30, 60 minutes and 2, 4, 6, 8, 10, 12, 24 and 32 hours post-dose.</time_frame>
    <description>To evaluate pharmacokinetic parameters of NAC in plasma after multiple dose administration of the investigational product.&#xD;
AUCss(0-12h)=AUC at steady-state from the last multiple dose to 12 hours post-dose, AUCss(0-t)=AUC at steady-state from the last multiple dose to the last observed concentration time t.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Accumulation Ratio After Multiple Doses of NAC</measure>
    <time_frame>On Day 4 and Day 5 -At pre-dose. On Day 6 and Day 7-At pre-dose (0) and 5 (at the end of the infusion), 8, 12, 15, 20, 25, 30, 60 minutes and 2, 4, 6, 8, 10, 12, 24 and 32 hours post-dose.</time_frame>
    <description>To evaluate pharmacokinetic parameters of NAC in plasma after multiple dose administration of the investigational product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total Amount of NAC Excreted in Urine From the Last Multiple Dose to 32 h at Steady-state [Aess(0-32)]</measure>
    <time_frame>On Day 4 and Day 5 -At pre-dose. On Day 6 and Day 7-At pre-dose (0) and 5 (at the end of the infusion), 8, 12, 15, 20, 25, 30, 60 minutes and 2, 4, 6, 8, 10, 12, 24 and 32 hours post-dose.</time_frame>
    <description>To evaluate pharmacokinetic parameters of NAC in plasma after multiple dose administration of the investigational product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Degree of Fluctuation Over One Dosing Interval at Steady-state (DF%) After Multiple Dose of NAC</measure>
    <time_frame>On Day 4 and Day 5 -At pre-dose. On Day 6 and Day 7-At pre-dose (0) and 5 (at the end of the infusion), 8, 12, 15, 20, 25, 30, 60 minutes and 2, 4, 6, 8, 10, 12, 24 and 32 hours post-dose.</time_frame>
    <description>To evaluate pharmacokinetic parameters of NAC in plasma after multiple dose administration of the investigational product.&#xD;
Degree of fluctuation over one dosing interval at steady-state is calculated as (Css_max - Css_min)/ Css_av*100</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>From screening to Final Visit/early termination visit (ETV, Day 8)</time_frame>
    <description>To collect safety and tolerability data after single and multiple dose administration of the investigational product.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Respiratory Tract Disorders</condition>
  <arm_group>
    <arm_group_label>Single dose regime of N-acetylcysteine (NAC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On day 1 at 08:00 ±1 hours, one dose of 600 mg of NAC (300 + 300 mg ampoule) will be administered under fasting conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple dose regime of N-acetylcysteine (NAC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On days 4 and 5 at 08:00 ±1 hours and 20:00 ±1 hours and at 08:00 ±1 on day 6, 5 doses of 600 mg of NAC (300 + 300 mg ampoule) will be administered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetylcysteine (NAC)</intervention_name>
    <description>Two ampoules of IMP (300 + 300 mg) corresponding to a total dose of 600 mg of NAC diluted in 10 mL of NaCl 0.9% sterile saline solution, will be administered by a 5-minute i.v. infusion.</description>
    <arm_group_label>Multiple dose regime of N-acetylcysteine (NAC)</arm_group_label>
    <arm_group_label>Single dose regime of N-acetylcysteine (NAC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Informed consent: signed written informed consent before inclusion in the study&#xD;
&#xD;
          2. Ethnicity, Sex and Age: Chinese males and females, 18-45 year old inclusive&#xD;
&#xD;
          3. Weight: body weight ≥50 kg&#xD;
&#xD;
          4. Body Mass Index: 19-26 kg/m2 inclusive&#xD;
&#xD;
          5. Vital signs: systolic blood pressure 100-139 mmHg, diastolic blood pressure 50-89&#xD;
             mmHg, heart rate 50-90 bpm, measured after 5 min at rest in the sitting/supine&#xD;
             position&#xD;
&#xD;
          6. Full comprehension: ability to comprehend the full nature and purpose of the study,&#xD;
             including possible risks and side effects; ability to co-operate with the investigator&#xD;
             and to comply with the requirements of the entire study&#xD;
&#xD;
          7. Nicotine addiction (smoker subjects only): ability to abstain from smoking for the&#xD;
             duration of the clinical study&#xD;
&#xD;
          8. Contraception and fertility (women only): women of child-bearing potential must be&#xD;
             using at least one of the following reliable methods of contraception:&#xD;
&#xD;
               1. Hormonal oral, implantable, transdermal, or injectable contraceptives for at&#xD;
                  least 60 calendar days before the screening visit&#xD;
&#xD;
               2. A non-hormonal intrauterine device or female condom with spermicide or&#xD;
                  contraceptive sponge with spermicide or diaphragm with spermicide or cervical cap&#xD;
                  with spermicide for at least 60 calendar days before the screening visit&#xD;
&#xD;
               3. A male sexual partner who agrees to use a male condom with spermicide&#xD;
&#xD;
               4. A sterile sexual partner&#xD;
&#xD;
        Women of non-child-bearing potential or in post-menopausal status for at least 1 year will&#xD;
        be admitted. Women of childbearing potential should be willing to adopt abstinence or&#xD;
        contraception measures during the study and two weeks post-dose. For all women, pregnancy&#xD;
        test result must be negative at screening and day -1.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Electrocardiogram (12-lead ECG in supine position): clinically significant&#xD;
             abnormalities&#xD;
&#xD;
          2. Physical findings: clinically significant abnormal physical findings which could&#xD;
             interfere with the objectives of the study&#xD;
&#xD;
          3. Laboratory analyses: clinically significant abnormal laboratory values indicative of&#xD;
             physical illness, in particular significant laboratory abnormality indicative of&#xD;
             hepatic condition (more than 3 times the upper limit)&#xD;
&#xD;
          4. Allergy: ascertained or presumptive hypersensitivity to the active principle and/or&#xD;
             formulations' ingredients; history of anaphylaxis to drugs or allergic reactions in&#xD;
             general, which the investigator considers may affect the outcome of the study&#xD;
&#xD;
          5. Diseases: significant history of renal, hepatic, gastrointestinal, cardiovascular,&#xD;
             respiratory, skin, haematological, endocrine, urologic, metabolic, neurological or&#xD;
             psychiatric diseases, as determined by the investigator, that may interfere with the&#xD;
             aim of the study; history of carcinoma in situ and malignant disease; active bacterial&#xD;
             or viral infection and fever &gt;38°C within 48 h prior to study treatment administration&#xD;
&#xD;
          6. Virology: positive result of HIV, hepatitis B (HBV), hepatitis C (HCV) or Treponema&#xD;
             pallidum (TP) assays&#xD;
&#xD;
          7. Surgery: any surgery within 60 calendar days of screening (excluding diagnostic&#xD;
             surgery)&#xD;
&#xD;
          8. Medications: medications, including over the counter (OTC) medications, herbal&#xD;
             remedies and traditional Chinese remedies for 2 weeks before the start of the study.&#xD;
             Hormonal contraceptives for women will be allowed&#xD;
&#xD;
          9. Investigative drug studies: participation in the evaluation of any investigational&#xD;
             product for 1 month before this study&#xD;
&#xD;
         10. Blood donation: blood donations for 90 calendar days before this study&#xD;
&#xD;
         11. Drug, alcohol, caffeine, tobacco: history of drug, alcohol [&gt;1 drink/day for females&#xD;
             and &gt;2 drinks/day for males, defined according to the USDA Dietary Guidelines&#xD;
             2015-2020] caffeine (&gt;5 cups coffee/tea/day) or tobacco abuse (≥10 cigarettes/day)&#xD;
&#xD;
         12. Abuse drug test: positive urine abuse drug test at screening or day -1&#xD;
&#xD;
         13. Alcohol test: positive alcohol breath test at day -1&#xD;
&#xD;
         14. Diet: abnormal diets (&lt;1600 or &gt;3500 kcal/day) or substantial changes in eating habits&#xD;
             in the 4 weeks before this study; vegetarians; consumption of alcohol, grapefruit,&#xD;
             products containing grapefruit, or beverages containing xanthines (coffee, tea, soda,&#xD;
             coffee with milk, energy drinks) within 48 hours prior to the enrolment&#xD;
&#xD;
         15. Pregnancy (females only): positive or missing pregnancy test at screening or day -1,&#xD;
             pregnant or lactating women&#xD;
&#xD;
         16. Vaccination within 4 weeks of study treatment&#xD;
&#xD;
         17. Other unspecified reasons that, in the opinion of the investigator, make the subject&#xD;
             unsuitable for enrolment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ruijin Hospital, Shanghai Jiao Tong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>No.197 Ruijin Er Road</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 18, 2019</study_first_submitted>
  <study_first_submitted_qc>March 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2019</study_first_posted>
  <results_first_submitted>December 26, 2020</results_first_submitted>
  <results_first_submitted_qc>December 26, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 20, 2021</results_first_posted>
  <last_update_submitted>February 2, 2021</last_update_submitted>
  <last_update_submitted_qc>February 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 3, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/63/NCT03881163/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 15, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/63/NCT03881163/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was a single center study conducted in China from 11 November 2019 to 18 January 2020. All participants randomized in the study received single and multiple doses of N-acetylcysteine (NAC).</recruitment_details>
      <pre_assignment_details>Participants who met the eligibility criteria at the Screening Visit (Day -14 to Day 1) were assigned to receive NAC.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Overall - NAC 600 mg</title>
          <description>All participants were dosed with NAC once daily (QD) at 08:00 ± 1 hour on Day 1 under fasting conditions, twice daily (BID) at 08:00 ± 1 hour and 20:00 ± 1 hour on Day 4 and Day 5 after one 3-day wash-out, and QD at 08:00 ± 1 hour on Day 6.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All enrolled participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Overall - NAC 600 mg</title>
          <description>All participants were dosed with NAC QD at 08:00 ± 1 hour on Day 1 under fasting conditions, BID at 08:00 ± 1 hour and 20:00 ± 1 hour on Day 4 and Day 5 after one 3-day wash-out, and QD at 08:00 ± 1 hour on Day 6.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.6" spread="5.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Chinese</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Peak Drug Concentration (Cmax) After Single Dose of NAC</title>
        <description>To evaluate pharmacokinetic parameters of NAC in plasma after single administration of the investigational product.</description>
        <time_frame>On Day 1 and Day 2-At pre-dose (0) and 5 (at the end of the infusion), 8, 12, 15, 20, 25, 30, 60 minutes and 2, 4, 6, 8, 10, 12, 24 and 32 hours post-dose</time_frame>
        <population>Pharmacokinetic (PK) set: all enrolled participants who fulfilled the study protocol requirements in terms of investigational medicinal product intake and had evaluable PK data readouts for the planned analyses, with no major deviations that might affect the PK results.</population>
        <group_list>
          <group group_id="O1">
            <title>Single Dose - NAC 600mg</title>
            <description>Participants who met the eligibility criteria at the Screening Visit were assigned to receive NAC. On day 1 at 08:00 ±1 hours, one dose of 600 mg of NAC (300 + 300 mg ampoule) was administered under fasting conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Drug Concentration (Cmax) After Single Dose of NAC</title>
          <description>To evaluate pharmacokinetic parameters of NAC in plasma after single administration of the investigational product.</description>
          <population>Pharmacokinetic (PK) set: all enrolled participants who fulfilled the study protocol requirements in terms of investigational medicinal product intake and had evaluable PK data readouts for the planned analyses, with no major deviations that might affect the PK results.</population>
          <units>µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.30" spread="30.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Achieve Cmax (Tmax) After Single Dose of NAC</title>
        <description>To evaluate pharmacokinetic parameters of NAC in plasma after single dose administration of the investigational product.</description>
        <time_frame>On Day 1 and Day 2-At pre-dose (0) and 5 (at the end of the infusion), 8, 12, 15, 20, 25, 30, 60 minutes and 2, 4, 6, 8, 10, 12, 24 and 32 hours post-dose.</time_frame>
        <population>Pharmacokinetic (PK) set: all enrolled participants who fulfilled the study protocol requirements in terms of investigational medicinal product intake and had evaluable PK data readouts for the planned analyses, with no major deviations that might affect the PK results.</population>
        <group_list>
          <group group_id="O1">
            <title>Single Dose - NAC 600mg</title>
            <description>Participants who met the eligibility criteria at the Screening Visit were assigned to receive NAC. On day 1 at 08:00 ±1 hours, one dose of 600 mg of NAC (300 + 300 mg ampoule) was administered under fasting conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Achieve Cmax (Tmax) After Single Dose of NAC</title>
          <description>To evaluate pharmacokinetic parameters of NAC in plasma after single dose administration of the investigational product.</description>
          <population>Pharmacokinetic (PK) set: all enrolled participants who fulfilled the study protocol requirements in terms of investigational medicinal product intake and had evaluable PK data readouts for the planned analyses, with no major deviations that might affect the PK results.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.083" lower_limit="0.08" upper_limit="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Terminal Elimination Rate Constant (Kel) After Single Dose of NAC</title>
        <description>To evaluate pharmacokinetic parameters of NAC in plasma after single dose administration of the investigational product.</description>
        <time_frame>On Day 1 and Day 2-At pre-dose (0) and 5 (at the end of the infusion), 8, 12, 15, 20, 25, 30, 60 minutes and 2, 4, 6, 8, 10, 12, 24 and 32 hours post-dose.</time_frame>
        <population>Pharmacokinetic (PK) set: all enrolled participants who fulfilled the study protocol requirements in terms of investigational medicinal product intake and had evaluable PK data readouts for the planned analyses, with no major deviations that might affect the PK results.</population>
        <group_list>
          <group group_id="O1">
            <title>Single Dose - NAC 600mg</title>
            <description>Participants who met the eligibility criteria at the Screening Visit were assigned to receive NAC. On day 1 at 08:00 ±1 hours, one dose of 600 mg of NAC (300 + 300 mg ampoule) was administered under fasting conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Rate Constant (Kel) After Single Dose of NAC</title>
          <description>To evaluate pharmacokinetic parameters of NAC in plasma after single dose administration of the investigational product.</description>
          <population>Pharmacokinetic (PK) set: all enrolled participants who fulfilled the study protocol requirements in terms of investigational medicinal product intake and had evaluable PK data readouts for the planned analyses, with no major deviations that might affect the PK results.</population>
          <units>1/hour</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09723" spread="56.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Half-life (t1/2) After Single Dose of NAC</title>
        <description>To evaluate pharmacokinetic parameters of NAC in plasma after single dose administration of the investigational product.</description>
        <time_frame>On Day 1 and Day 2-At pre-dose (0) and 5 (at the end of the infusion), 8, 12, 15, 20, 25, 30, 60 minutes and 2, 4, 6, 8, 10, 12, 24 and 32 hours post-dose.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Dose - NAC 600mg</title>
            <description>Participants who met the eligibility criteria at the Screening Visit were assigned to receive NAC. On day 1 at 08:00 ±1 hours, one dose of 600 mg of NAC (300 + 300 mg ampoule) was administered under fasting conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Half-life (t1/2) After Single Dose of NAC</title>
          <description>To evaluate pharmacokinetic parameters of NAC in plasma after single dose administration of the investigational product.</description>
          <units>hour</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.129" spread="56.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-time Curve (AUC) After Single Dose of NAC</title>
        <description>To evaluate pharmacokinetic parameters of NAC in plasma after single dose administration of the investigational product.</description>
        <time_frame>On Day 1 and Day 2-At pre-dose (0) and 5 (at the end of the infusion), 8, 12, 15, 20, 25, 30, 60 minutes and 2, 4, 6, 8, 10, 12, 24 and 32 hours post-dose.</time_frame>
        <population>Pharmacokinetic (PK) set: all enrolled participants who fulfilled the study protocol requirements in terms of investigational medicinal product intake and had evaluable PK data readouts for the planned analyses, with no major deviations that might affect the PK results.</population>
        <group_list>
          <group group_id="O1">
            <title>Single Dose - NAC 600mg</title>
            <description>Participants who met the eligibility criteria at the Screening Visit were assigned to receive NAC. On day 1 at 08:00 ±1 hours, one dose of 600 mg of NAC (300 + 300 mg ampoule) was administered under fasting conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve (AUC) After Single Dose of NAC</title>
          <description>To evaluate pharmacokinetic parameters of NAC in plasma after single dose administration of the investigational product.</description>
          <population>Pharmacokinetic (PK) set: all enrolled participants who fulfilled the study protocol requirements in terms of investigational medicinal product intake and had evaluable PK data readouts for the planned analyses, with no major deviations that might affect the PK results.</population>
          <units>h*µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC from time zero to the last observed concentration time t [AUC(0-t)]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.16" spread="17.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC extrapolated to infinity [AUC(0-inf)]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.94" spread="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC from time zero to 12 hours post-dose [AUC(0-12h)]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.87" spread="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Volume of Distribution (Vd) After Single Dose of NAC</title>
        <description>To evaluate pharmacokinetic parameters of NAC in plasma after single dose administration of the investigational product.</description>
        <time_frame>On Day 1 and Day 2-At pre-dose (0) and 5 (at the end of the infusion), 8, 12, 15, 20, 25, 30, 60 minutes and 2, 4, 6, 8, 10, 12, 24 and 32 hours post-dose.</time_frame>
        <population>Pharmacokinetic (PK) set: all enrolled participants who fulfilled the study protocol requirements in terms of investigational medicinal product intake and had evaluable PK data readouts for the planned analyses, with no major deviations that might affect the PK results.</population>
        <group_list>
          <group group_id="O1">
            <title>Single Dose - NAC 600mg</title>
            <description>Participants who met the eligibility criteria at the Screening Visit were assigned to receive NAC. On day 1 at 08:00 ±1 hours, one dose of 600 mg of NAC (300 + 300 mg ampoule) was administered under fasting conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution (Vd) After Single Dose of NAC</title>
          <description>To evaluate pharmacokinetic parameters of NAC in plasma after single dose administration of the investigational product.</description>
          <population>Pharmacokinetic (PK) set: all enrolled participants who fulfilled the study protocol requirements in terms of investigational medicinal product intake and had evaluable PK data readouts for the planned analyses, with no major deviations that might affect the PK results.</population>
          <units>litre</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.69" spread="44.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Body Clearance (CLt) After Single Dose of NAC</title>
        <description>To evaluate pharmacokinetic parameters of NAC in plasma after single dose administration of the investigational product.</description>
        <time_frame>On Day 1 and Day 2-At pre-dose (0) and 5 (at the end of the infusion), 8, 12, 15, 20, 25, 30, 60 minutes and 2, 4, 6, 8, 10, 12, 24 and 32 hours post-dose.</time_frame>
        <population>Pharmacokinetic (PK) set: all enrolled participants who fulfilled the study protocol requirements in terms of investigational medicinal product intake and had evaluable PK data readouts for the planned analyses, with no major deviations that might affect the PK results.</population>
        <group_list>
          <group group_id="O1">
            <title>Single Dose - NAC 600mg</title>
            <description>Participants who met the eligibility criteria at the Screening Visit were assigned to receive NAC. On day 1 at 08:00 ±1 hours, one dose of 600 mg of NAC (300 + 300 mg ampoule) was administered under fasting conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Body Clearance (CLt) After Single Dose of NAC</title>
          <description>To evaluate pharmacokinetic parameters of NAC in plasma after single dose administration of the investigational product.</description>
          <population>Pharmacokinetic (PK) set: all enrolled participants who fulfilled the study protocol requirements in terms of investigational medicinal product intake and had evaluable PK data readouts for the planned analyses, with no major deviations that might affect the PK results.</population>
          <units>Liter\hour</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.387" spread="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Amount of NAC Excreted in Urine [Ae(0-t)] After Single Dose of NAC</title>
        <description>To evaluate pharmacokinetic parameters of NAC in plasma after single dose administration of the investigational product.</description>
        <time_frame>On Day 1 and Day 2-At pre-dose (0) and 5 (at the end of the infusion), 8, 12, 15, 20, 25, 30, 60 minutes and 2, 4, 6, 8, 10, 12, 24 and 32 hours post-dose.</time_frame>
        <population>Pharmacokinetic (PK) set: all enrolled participants who fulfilled the study protocol requirements in terms of investigational medicinal product intake and had evaluable PK data readouts for the planned analyses, with no major deviations that might affect the PK results.</population>
        <group_list>
          <group group_id="O1">
            <title>Single Dose - NAC 600mg</title>
            <description>Participants who met the eligibility criteria at the Screening Visit were assigned to receive NAC. On day 1 at 08:00 ±1 hours, one dose of 600 mg of NAC (300 + 300 mg ampoule) was administered under fasting conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Amount of NAC Excreted in Urine [Ae(0-t)] After Single Dose of NAC</title>
          <description>To evaluate pharmacokinetic parameters of NAC in plasma after single dose administration of the investigational product.</description>
          <population>Pharmacokinetic (PK) set: all enrolled participants who fulfilled the study protocol requirements in terms of investigational medicinal product intake and had evaluable PK data readouts for the planned analyses, with no major deviations that might affect the PK results.</population>
          <units>μg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ae(0-4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62750" spread="76.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ae(4-8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16170" spread="55.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ae(8-12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3609" spread="155.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ae(12-24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1846" spread="78.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ae(24-32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1366" spread="63.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ae(0-8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84020" spread="53.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ae(0-12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89600" spread="50.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ae(0-24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92020" spread="49.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ae(0-32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93490" spread="48.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Fraction of NAC Dose Excreted in Urine [Fe(0-t)] After Single Dose of NAC</title>
        <description>To evaluate pharmacokinetic parameters of NAC in plasma after single dose administration of the investigational product.</description>
        <time_frame>On Day 1 and Day 2-At pre-dose (0) and 5 (at the end of the infusion), 8, 12, 15, 20, 25, 30, 60 minutes and 2, 4, 6, 8, 10, 12, 24 and 32 hours post-dose.</time_frame>
        <population>Pharmacokinetic (PK) set: all enrolled participants who fulfilled the study protocol requirements in terms of investigational medicinal product intake and had evaluable PK data readouts for the planned analyses, with no major deviations that might affect the PK results.</population>
        <group_list>
          <group group_id="O1">
            <title>Single Dose - NAC 600mg</title>
            <description>Participants who met the eligibility criteria at the Screening Visit were assigned to receive NAC. On day 1 at 08:00 ±1 hours, one dose of 600 mg of NAC (300 + 300 mg ampoule) was administered under fasting conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Fraction of NAC Dose Excreted in Urine [Fe(0-t)] After Single Dose of NAC</title>
          <description>To evaluate pharmacokinetic parameters of NAC in plasma after single dose administration of the investigational product.</description>
          <population>Pharmacokinetic (PK) set: all enrolled participants who fulfilled the study protocol requirements in terms of investigational medicinal product intake and had evaluable PK data readouts for the planned analyses, with no major deviations that might affect the PK results.</population>
          <units>fraction</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fe(0-4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1046" spread="76.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe(0-8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1400" spread="53.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe(0-12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1493" spread="50.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe(0-24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1534" spread="49.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fe(0-32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1558" spread="48.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Renal Clearance (CLr) After Single Dose of NAC</title>
        <description>To evaluate pharmacokinetic parameters of NAC in plasma after single dose administration of the investigational product.</description>
        <time_frame>On Day 1 and Day 2-At pre-dose (0) and 5 (at the end of the infusion), 8, 12, 15, 20, 25, 30, 60 minutes and 2, 4, 6, 8, 10, 12, 24 and 32 hours post-dose.</time_frame>
        <population>Pharmacokinetic (PK) set: all enrolled participants who fulfilled the study protocol requirements in terms of investigational medicinal product intake and had evaluable PK data readouts for the planned analyses, with no major deviations that might affect the PK results.</population>
        <group_list>
          <group group_id="O1">
            <title>Single Dose - NAC 600mg</title>
            <description>Participants who met the eligibility criteria at the Screening Visit were assigned to receive NAC. On day 1 at 08:00 ±1 hours, one dose of 600 mg of NAC (300 + 300 mg ampoule) was administered under fasting conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Clearance (CLr) After Single Dose of NAC</title>
          <description>To evaluate pharmacokinetic parameters of NAC in plasma after single dose administration of the investigational product.</description>
          <population>Pharmacokinetic (PK) set: all enrolled participants who fulfilled the study protocol requirements in terms of investigational medicinal product intake and had evaluable PK data readouts for the planned analyses, with no major deviations that might affect the PK results.</population>
          <units>mL/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="995.2" spread="50.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of the AUC(0-inf) Obtained by Extrapolation (%AUCextra)</title>
        <description>To evaluate pharmacokinetic parameters of NAC in plasma after single dose administration of the investigational product.</description>
        <time_frame>On Day 1 and Day 2-At pre-dose (0) and 5 (at the end of the infusion), 8, 12, 15, 20, 25, 30, 60 minutes and 2, 4, 6, 8, 10, 12, 24 and 32 hours post-dose.</time_frame>
        <population>Pharmacokinetic (PK) set: all enrolled participants who fulfilled the study protocol requirements in terms of investigational medicinal product intake and had evaluable PK data readouts for the planned analyses, with no major deviations that might affect the PK results.</population>
        <group_list>
          <group group_id="O1">
            <title>Single Dose - NAC 600mg</title>
            <description>Participants who met the eligibility criteria at the Screening Visit were assigned to receive NAC. On day 1 at 08:00 ±1 hours, one dose of 600 mg of NAC (300 + 300 mg ampoule) was administered under fasting conditions.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of the AUC(0-inf) Obtained by Extrapolation (%AUCextra)</title>
          <description>To evaluate pharmacokinetic parameters of NAC in plasma after single dose administration of the investigational product.</description>
          <population>Pharmacokinetic (PK) set: all enrolled participants who fulfilled the study protocol requirements in terms of investigational medicinal product intake and had evaluable PK data readouts for the planned analyses, with no major deviations that might affect the PK results.</population>
          <units>percentage</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.967" spread="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Concentration at Steady-state After Multiple Doses of NAC</title>
        <description>To evaluate pharmacokinetic parameters of NAC in plasma after multiple dose administration of the investigational product.&#xD;
Css_max = maximum NAC plasma concentration at steady-state, Css_min=minimum plasma concentration at steady-state, Css_avg=average NAC plasma concentration at steady-state.</description>
        <time_frame>On Day 4 and Day 5 -At pre-dose. On Day 6 and Day 7-At pre-dose (0) and 5 (at the end of the infusion), 8, 12, 15, 20, 25, 30, 60 minutes and 2, 4, 6, 8, 10, 12, 24 and 32 hours post-dose.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Multiple Dose - NAC 600mg</title>
            <description>Participants who met the eligibility criteria at the Screening Visit were assigned to receive NAC. On days 4 and 5 at 08:00 ±1 hours and 20:00 ±1 hours and at 08:00 ±1 on day 6, 5 doses of 600 mg of NAC (300 + 300 mg ampoule) will be administered.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration at Steady-state After Multiple Doses of NAC</title>
          <description>To evaluate pharmacokinetic parameters of NAC in plasma after multiple dose administration of the investigational product.&#xD;
Css_max = maximum NAC plasma concentration at steady-state, Css_min=minimum plasma concentration at steady-state, Css_avg=average NAC plasma concentration at steady-state.</description>
          <units>µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Css_max</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.8" spread="29.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Css_min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.899" spread="20.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Css_avg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.719" spread="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Achieve Css_max (tss_max) After Multiple Doses of NAC</title>
        <description>To evaluate pharmacokinetic parameters of NAC in plasma after multiple dose administration of the investigational product.</description>
        <time_frame>On Day 4 and Day 5 -At pre-dose. On Day 6 and Day 7-At pre-dose (0) and 5 (at the end of the infusion), 8, 12, 15, 20, 25, 30, 60 minutes and 2, 4, 6, 8, 10, 12, 24 and 32 hours post-dose.</time_frame>
        <population>Pharmacokinetic (PK) set: all participants who fulfilled the study protocol requirements in terms of investigational medicinal product intake and had evaluable PK data readouts for the planned analyses, with no major deviations that might affect the PK results.</population>
        <group_list>
          <group group_id="O1">
            <title>Multiple Dose - NAC 600mg</title>
            <description>Participants who met the eligibility criteria at the Screening Visit were assigned to receive NAC. On days 4 and 5 at 08:00 ±1 hours and 20:00 ±1 hours and at 08:00 ±1 on day 6, 5 doses of 600 mg of NAC (300 + 300 mg ampoule) will be administered.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Achieve Css_max (tss_max) After Multiple Doses of NAC</title>
          <description>To evaluate pharmacokinetic parameters of NAC in plasma after multiple dose administration of the investigational product.</description>
          <population>Pharmacokinetic (PK) set: all participants who fulfilled the study protocol requirements in terms of investigational medicinal product intake and had evaluable PK data readouts for the planned analyses, with no major deviations that might affect the PK results.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.083" lower_limit="0.07" upper_limit="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-time Curve at Steady State After Multiple Doses of NAC</title>
        <description>To evaluate pharmacokinetic parameters of NAC in plasma after multiple dose administration of the investigational product.&#xD;
AUCss(0-12h)=AUC at steady-state from the last multiple dose to 12 hours post-dose, AUCss(0-t)=AUC at steady-state from the last multiple dose to the last observed concentration time t.</description>
        <time_frame>On Day 4 and Day 5 -At pre-dose. On Day 6 and Day 7-At pre-dose (0) and 5 (at the end of the infusion), 8, 12, 15, 20, 25, 30, 60 minutes and 2, 4, 6, 8, 10, 12, 24 and 32 hours post-dose.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Multiple Dose - NAC 600mg</title>
            <description>Participants who met the eligibility criteria at the Screening Visit were assigned to receive NAC. On days 4 and 5 at 08:00 ±1 hours and 20:00 ±1 hours and at 08:00 ±1 on day 6, 5 doses of 600 mg of NAC (300 + 300 mg ampoule) will be administered.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve at Steady State After Multiple Doses of NAC</title>
          <description>To evaluate pharmacokinetic parameters of NAC in plasma after multiple dose administration of the investigational product.&#xD;
AUCss(0-12h)=AUC at steady-state from the last multiple dose to 12 hours post-dose, AUCss(0-t)=AUC at steady-state from the last multiple dose to the last observed concentration time t.</description>
          <units>h*µg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUCss(0-t)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.6" spread="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUCss(0-12h)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.63" spread="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Accumulation Ratio After Multiple Doses of NAC</title>
        <description>To evaluate pharmacokinetic parameters of NAC in plasma after multiple dose administration of the investigational product.</description>
        <time_frame>On Day 4 and Day 5 -At pre-dose. On Day 6 and Day 7-At pre-dose (0) and 5 (at the end of the infusion), 8, 12, 15, 20, 25, 30, 60 minutes and 2, 4, 6, 8, 10, 12, 24 and 32 hours post-dose.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Multiple Dose - NAC 600mg</title>
            <description>Participants who met the eligibility criteria at the Screening Visit were assigned to receive NAC. On days 4 and 5 at 08:00 ±1 hours and 20:00 ±1 hours and at 08:00 ±1 on day 6, 5 doses of 600 mg of NAC (300 + 300 mg ampoule) will be administered.</description>
          </group>
        </group_list>
        <measure>
          <title>Accumulation Ratio After Multiple Doses of NAC</title>
          <description>To evaluate pharmacokinetic parameters of NAC in plasma after multiple dose administration of the investigational product.</description>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.132" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total Amount of NAC Excreted in Urine From the Last Multiple Dose to 32 h at Steady-state [Aess(0-32)]</title>
        <description>To evaluate pharmacokinetic parameters of NAC in plasma after multiple dose administration of the investigational product.</description>
        <time_frame>On Day 4 and Day 5 -At pre-dose. On Day 6 and Day 7-At pre-dose (0) and 5 (at the end of the infusion), 8, 12, 15, 20, 25, 30, 60 minutes and 2, 4, 6, 8, 10, 12, 24 and 32 hours post-dose.</time_frame>
        <population>Pharmacokinetic (PK) set: all enrolled participants who fulfilled the study protocol requirements in terms of investigational medicinal product intake and had evaluable PK data readouts for the planned analyses, with no major deviations that might affect the PK results.</population>
        <group_list>
          <group group_id="O1">
            <title>Multiple Dose - NAC 600mg</title>
            <description>Participants who met the eligibility criteria at the Screening Visit were assigned to receive NAC. On days 4 and 5 at 08:00 ±1 hours and 20:00 ±1 hours and at 08:00 ±1 on day 6, 5 doses of 600 mg of NAC (300 + 300 mg ampoule) will be administered.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Amount of NAC Excreted in Urine From the Last Multiple Dose to 32 h at Steady-state [Aess(0-32)]</title>
          <description>To evaluate pharmacokinetic parameters of NAC in plasma after multiple dose administration of the investigational product.</description>
          <population>Pharmacokinetic (PK) set: all enrolled participants who fulfilled the study protocol requirements in terms of investigational medicinal product intake and had evaluable PK data readouts for the planned analyses, with no major deviations that might affect the PK results.</population>
          <units>μg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68980" spread="68.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Degree of Fluctuation Over One Dosing Interval at Steady-state (DF%) After Multiple Dose of NAC</title>
        <description>To evaluate pharmacokinetic parameters of NAC in plasma after multiple dose administration of the investigational product.&#xD;
Degree of fluctuation over one dosing interval at steady-state is calculated as (Css_max - Css_min)/ Css_av*100</description>
        <time_frame>On Day 4 and Day 5 -At pre-dose. On Day 6 and Day 7-At pre-dose (0) and 5 (at the end of the infusion), 8, 12, 15, 20, 25, 30, 60 minutes and 2, 4, 6, 8, 10, 12, 24 and 32 hours post-dose.</time_frame>
        <population>Pharmacokinetic (PK) set: all enrolled participants who fulfilled the study protocol requirements in terms of investigational medicinal product intake and had evaluable PK data readouts for the planned analyses, with no major deviations that might affect the PK results.</population>
        <group_list>
          <group group_id="O1">
            <title>Multiple Dose - NAC 600mg</title>
            <description>Participants who met the eligibility criteria at the Screening Visit were assigned to receive NAC. On days 4 and 5 at 08:00 ±1 hours and 20:00 ±1 hours and at 08:00 ±1 on day 6, 5 doses of 600 mg of NAC (300 + 300 mg ampoule) will be administered.</description>
          </group>
        </group_list>
        <measure>
          <title>Degree of Fluctuation Over One Dosing Interval at Steady-state (DF%) After Multiple Dose of NAC</title>
          <description>To evaluate pharmacokinetic parameters of NAC in plasma after multiple dose administration of the investigational product.&#xD;
Degree of fluctuation over one dosing interval at steady-state is calculated as (Css_max - Css_min)/ Css_av*100</description>
          <population>Pharmacokinetic (PK) set: all enrolled participants who fulfilled the study protocol requirements in terms of investigational medicinal product intake and had evaluable PK data readouts for the planned analyses, with no major deviations that might affect the PK results.</population>
          <units>percentage</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1279" spread="30.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment Emergent Adverse Events (TEAEs)</title>
        <description>To collect safety and tolerability data after single and multiple dose administration of the investigational product.</description>
        <time_frame>From screening to Final Visit/early termination visit (ETV, Day 8)</time_frame>
        <population>Safety set: All participants who received at least one dose of investigational medicinal product.</population>
        <group_list>
          <group group_id="O1">
            <title>NAC 600 mg</title>
            <description>All participants were dosed with NAC once daily (QD) at 08:00 ± 1 hour on Day 1 under fasting conditions, BID at 08:00 ± 1 hour and 20:00 ± 1 hour on Day 4 and Day 5 after one 3-day wash-out, and QD at 08:00 ± 1 hour on Day 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Emergent Adverse Events (TEAEs)</title>
          <description>To collect safety and tolerability data after single and multiple dose administration of the investigational product.</description>
          <population>Safety set: All participants who received at least one dose of investigational medicinal product.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any TEAE Related to investigational medicinal product</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From Screening to Final Visit/Early termination (ETV, Day 8)</time_frame>
      <desc>All AEs/serious adverse events (SAEs), regardless of the relationship to investigational medicinal product, were to be assessed and recorded from the date the informed content form was signed until Final Visit/ETV.</desc>
      <group_list>
        <group group_id="E1">
          <title>Overall - NAC 600 mg</title>
          <description>All participants were dosed with NAC once daily (QD) at 08:00 ± 1 hour on Day 1 under fasting conditions, BID at 08:00 ± 1 hour and 20:00 ± 1 hour on Day 4 and Day 5 after one 3-day wash-out, and QD at 08:00 ± 1 hour on Day 6.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 22.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Retching</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Urine output increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Valentina Vaja</name_or_title>
      <organization>Zambon S.p.A</organization>
      <phone>+390266524497</phone>
      <email>Valentina.Vaja@ZambonGroup.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

